General Archives - Humane Genomics

New Home at Alexandria LaunchLabs

July 3, 2025 Rupsa Basu 0 Comment

We have officially moved from our founding location at BioLabs@NYU Langone to Alexandria LaunchLabs, a leading life sciences innovation space in New York City. This move marks another step forward in our mission to develop next-generation oncolytic viruses for cancer therapy. Why This Move Matters Relocating our lab, to us, is more than a logistical undertaking—it reflects the evolution of our platform and the increasing scale of our research. Over the past few years, BioLabs@NYU Langone provided an environment that…

Reflections from AACR 2025: Advancing Oncolytic Viral Therapies (OVTs)

May 19, 2025 Chad Moles 0 Comment

We recently had the opportunity to attend the 2025 American Association for Cancer Research (AACR) conference in Chicago. It is one of the largest and most prestigious gatherings in the world for cancer researchers, clinicians, and biotech companies. It was an invaluable experience—an opportunity not only to present our latest findings but also to connect with peers and explore the exciting evolution of oncolytic viral therapies (OVTs). Here’s a recap of the key trends we observed and how they align…

Showcasing data on our oncolytic viral therapy at AACR 2025

April 22, 2025 Chad Moles 0 Comment

We showcase breakthrough data on our engineered oncolytic viral therapy, a first-in-class for pediatric liver cancer We are excited to share that Humane Genomics is returning to the American Association for Cancer Research (AACR) annual meeting for the third time! With over 23,000 attendees (in 2024), AACR is the largest gathering of cancer researchers, clinicians, survivors, and advocates in the world. It is an honor to be invited back to this prestigious event where we will be showcasing our groundbreaking…

Improving the success rate of engineering RNA viruses

November 21, 2024 Chad Moles 0 Comment

In our previous post on this topic, we introduced the details on how to make a replicating RNA virus from its genome (DNA). In this post, we want to zoom in on the details a bit more and share how we have improved the success rate of engineering viruses to over 70%. If you have not read the previous post on the science of viral engineering and want to get a first level understanding on how the process works, go…

The Role of miRNA in Modern Medicine and the Nobel Prize Recognition

October 7, 2024 pete 0 Comment

Today, the 2024 Nobel Prize in Medicine was awarded to Victor Ambros and Gary Ruvkun for their groundbreaking discovery of microRNAs (miRNAs). This discovery has transformed our understanding of how cells regulate genes and opened new possibilities for diagnosing and treating diseases. But what exactly are miRNAs, and why are they so significant? What Are miRNAs? miRNAs are tiny pieces of RNA, typically about 22 nucleotides long, that act as master regulators in cells. They don’t code for proteins themselves…

The Science of Engineering Viruses

May 5, 2024 Chad Moles 0 Comment

Introduction Have you ever wondered how viruses are made in a lab setting? Although it may sound like complex wizardry, the process is quite approachable with a bit of molecular biology under your belt. This blog post will try to explain the process of engineering viruses, making it hopefully understandable to anyone curious about the steps involved. Understanding Virus Structure Fig.1. Simplified viral structure Before diving into virus creation, it is essential to understand what a virus consists of, in…

Reflections from AACR: The evolving landscape of Oncolytic Viral Therapies

April 22, 2024 Chad Moles 0 Comment

We recently attended the American Association for Cancer Research (AACR) conference. It’s the largest cancer research gathering in the U.S., and we were thrilled to present our latest results and learn from peers. Here’s a snapshot of the current developments in oncolytic viral therapies (OVTs). The State of Oncolytic Viral Therapies Diverse Targets and Approaches:Presentations at AACR showed a strong interest in OVTs, featuring 39 oncolytic viruses from 23 companies and 11 research groups. These therapies aim to combat a…

Join Us at AACR 2024: Celebrating Progress in Cancer Research

April 3, 2024 pete 0 Comment

We’re thrilled to announce that we’re returning to the American Association for Cancer Research (AACR) annual meeting for the second time! It’s an honor to be invited back to this prestigious event where we’ll be showcasing our groundbreaking work in the field of cancer therapeutics. AACR is the largest gathering of cancer researchers, clinicians, survivors, and advocates in the world, with over 20,000 attendees. Our Progress Since Last Year Last year’s experience in Orlando was unforgettable. We connected with fellow…

Engineering selective infection

December 11, 2023 pete 3 comments

How viruses infect cells is key to developing safe oncolytic viral therapies. In this post we discuss how viruses can be engineered to target cancer cells. The infection process begins when a virus recognizes and attaches to a host cell. This attachment is typically mediated by viral proteins known as glycoproteins, which specifically bind to receptors on the surface of the target cell. These glycoproteins act like keys, unlocking the door to the cell by interacting with specific cell surface…

Regulating viral replication using RNA aptazymes

August 28, 2023 Chad Moles 0 Comment

The biggest problem in cancer therapeutics is selectivity. Using oncolytic viral therapies, high selectivity can be achieved using the combination of selective infection and selective replication. Here, we want to address selective replication. For DNA viruses, this can be accomplished with promoters to control transcription and genome replication. However, for RNA viruses, this does not work. A potential solution to control replication for RNA viruses is the use of aptazymes. Aptazymes are self-cleaving units composed of a riboswitch and an aptamer….